Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 5, 352-359 p.Article in journal (Refereed) Published
Objective: The aim of this study was to investigate the impact of bone metastasis on survival and quality of life (QoL) in men with hormone-naive prostate cancer. Materials and methods: The study included 900 patients from a randomized trial (No. 5) by the Scandinavian Prostate Cancer Group, comparing parenteral oestrogen with total androgen blockade. Extent of bone metastasis was categorized according to a modified Soloway score: score 1, n=319; score 2, n = 483; and score 3, n = 98 patients. The primary outcome measurements were mean differences in QoL and overall survival. Results: QoL rating scales showed a decrease with increasing extent of bone metastasis (p amp;lt; 0.001). The mean global health status decreased from 64.4 to 50.5 for Soloway score 1 and 3, respectively. Following adjustment for performance status, analgesic consumption, grade of malignancy, alkaline phosphatase, prostate-specific antigen, haemoglobin and global health status, Soloway score 2 and 3 had a 47% [hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.21-1.80] and 78% (HR 1.78 95%, CI 1.32-2.42) increased mortality, respectively, compared to Soloway score 1. Independent predictive factors of mortality were assessed. Conclusions: Patient grouping based on three categories of extent of bone metastasis related to performance status, haemoglobin and global health status at presentation, as independent predictors of mortality, may provide improved accuracy of prognosis.
Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2016. Vol. 50, no 5, 352-359 p.
Androgen deprivation treatment; bone metastasis; extent of disease; hormone-naive; predictors of survival; prostate cancer
Urology and Nephrology
IdentifiersURN: urn:nbn:se:liu:diva-132207DOI: 10.1080/21681805.2016.1209689ISI: 000384068000005PubMedID: 27603423OAI: oai:DiVA.org:liu-132207DiVA: diva2:1043951
Funding Agencies|Ferring AB, Malmo, Sweden; Ferring Laegemidler A/S, Copenhagen, Denmark; Pharmacia AB, Uppsala, Sweden; Schering-Plough AB, Stockholm, Sweden2016-11-012016-10-212016-11-30